SCHEMBL2705515

SCHEMBL2705515

O=C1c2ccccc2N(S(=O)(=O)c2ccc(Cl)cc2)CC1C(=O)C(F)F

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KCNA3 P22001 3/20 0.51
▸ KCNN4 O15554 2/20 0.51
▸ PSEN1 P49768 3/20 0.43
▸ PSEN2 P49810 3/20 0.43
▸ APH1B Q8WW43 3/20 0.43
▸ NCSTN Q92542 3/20 0.43
▸ APH1A Q96BI3 3/20 0.43
▸ PSENEN Q9NZ42 3/20 0.43
▸ MEN1 O00255 5/20 0.43
▸ KMT2A Q03164 5/20 0.43
▸ MMP2 P08253 5/20 0.40
▸ ALDH1A1 P00352 2/20 0.38
▸ MCL1 Q07820 1/20 0.38
▸ MMP9 P14780 4/20 0.38
▸ HSD11B1 P28845 1/20 0.37
▸ MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2705838 0.80 MEN1 (0.55) KCNA3KCNN4PSEN1PSEN2APH1B
SCHEMBL2705273 0.78 ALDH1A1 (0.48) KCNA3KCNN4PSEN1PSEN2APH1B
SCHEMBL2703792 0.74 KCNA3 (0.52) KCNA3KCNN4PSEN1PSEN2APH1B
SCHEMBL2705507 0.68 KMT2A (0.68) KCNA3KCNN4PSEN1PSEN2APH1B
SCHEMBL3041480 0.68 KCNA3 (1.00) KCNA3KCNN4PSEN1PSEN2APH1B
SCHEMBL28556866 0.68 KCNN4 (0.59) KCNA3KCNN4MMP2
SCHEMBL28857559 0.67 KCNN4 (0.52) KCNA3KCNN4MEN1KMT2AMMP2
SCHEMBL2702360 0.67 ALDH1A1 (0.46) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL28565985 0.66 KCNN4 (0.60) KCNA3KCNN4MMP2
SCHEMBL8357256 0.66 MEN1 (0.60) KCNA3KCNN4PSEN1PSEN2APH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2450358-A1 Fused, tricyclic sulfonamide inhibitors of gamma secretase Elan Pharmaceuticals Inc. (US) 2012-05-09 — — EP disclosed
US-20080021056-A1 Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. 2008-01-24 — — US disclosed
US-20080021056-A1 Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. 2008-01-24 — — US disclosed
US-20080021056-A1 Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. 2008-01-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021056-A1 Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase BACE1, BACE2, PSEN1 KCNA3 2000/4885KCNN4 3516/4885PSEN1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback